These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34638381)

  • 1. Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity.
    Todoerti K; Taiana E; Puccio N; Favasuli V; Lionetti M; Silvestris I; Gentile M; Musto P; Morabito F; Gianelli U; Bolli N; Baldini L; Neri A; Ronchetti D
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report.
    Yang Y; Fu LJ; Chen CM; Hu MW
    World J Clin Cases; 2021 Feb; 9(5):1175-1183. PubMed ID: 33644182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
    Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
    Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.
    Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC
    Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
    Cazaubiel T; Leleu X; Perrot A; Manier S; Buisson L; Maheo S; Do Souto Ferreira L; Lannes R; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Schavgoulidze A; Avet-Loiseau H; Corre J
    Blood; 2022 Apr; 139(17):2666-2672. PubMed ID: 35171994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review.
    Valliani S; Ali M; Mahmoo O; Hinduja S; Chen CK; Damon L; Abdulhaq H
    Case Rep Hematol; 2020; 2020():8823877. PubMed ID: 33425404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
    Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A
    Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Gonsalves WI; Buadi FK; Kumar SK
    Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global methylation patterns in primary plasma cell leukemia.
    Todoerti K; Calice G; Trino S; Simeon V; Lionetti M; Manzoni M; Fabris S; Barbieri M; Pompa A; Baldini L; Bollati V; Zoppoli P; Neri A; Musto P
    Leuk Res; 2018 Oct; 73():95-102. PubMed ID: 30257227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
    Schinke C; Boyle EM; Ashby C; Wang Y; Lyzogubov V; Wardell C; Qu P; Hoering A; Deshpande S; Ryan K; Thanendrarajan S; Mohan M; Yarlagadda N; Khan M; Choudhury SR; Zangari M; van Rhee F; Davies F; Barlogie B; Morgan G; Walker BA
    Blood Cancer J; 2020 Jun; 10(6):70. PubMed ID: 32555163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database.
    Ge X; Meng W; Wang W; Ma H; Zhao S; Cui K
    Medicine (Baltimore); 2022 Jul; 101(29):e29578. PubMed ID: 35866755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
    Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
    Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-Hit Primary Plasma Cell Leukemia with
    Yasumi M; Endo T; Sata H; Karasuno T
    Case Rep Hematol; 2020; 2020():8811114. PubMed ID: 33381329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.
    Usmani SZ; Nair B; Qu P; Hansen E; Zhang Q; Petty N; Waheed S; Shaughnessy JD; Alsayed Y; Heuck CJ; van Rhee F; Milner T; Hoering A; Szymonifka J; Sexton R; Sawyer J; Singh Z; Crowley J; Barlogie B
    Leukemia; 2012 Nov; 26(11):2398-405. PubMed ID: 22508408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
    Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Månsson R; Wagner AK; Alici E
    Am J Hematol; 2021 Aug; 96(8):925-933. PubMed ID: 33901326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.